FDA closer to approving Botox for migraines

Allergan said in its second-quarter earnings statement the FDA had requested information about how the company could safely market Botox to treat migraines.

Allergan said in its second-quarter earnings statement the FDA had requested information about how the company could safely market Botox to treat migraines.

Although the FDA added three months to the review process, analysts reported the federal agency is likely to approve Botox as a treatment for migraines. Last month, the company won approval in the UK to market Botox for migraine prevention.

Reuters writes: "Investors had expected the US Food and Drug Administration to decide by Monday whether to approve use of Botox to treat migraines, an indication that could help turbo charge already blockbuster sales of Allergan's biggest product."

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in